头颈癌手术患者术前不良事件风险指数的评估
该研究基于美国外科医师学会国家手术质量改进计划2006至2016年数据,纳入31399例头颈癌手术患者,开发并验证了术前头颈手术风险指数(HNSRI)。验证队列(n=15699)中HNSRI预测主要术后不良事件(含死亡)的AUC为0.84,灵敏度80.1%、特异度72.3%,优于改良衰弱指数11、美国麻醉医师学会分级和ACS风险计算器。
要点
- HNSRI预测主要术后不良事件(含30天内死亡)的AUC为0.84(95%CI 0.83-0.85),灵敏度80.1%、特异度72.3%。
- HNSRI优于改良衰弱指数11(delta C指数0.23)、ASA分级(0.14)和ACS风险计算器(0.02)。
- HNSRI可用于术前与等待头颈癌手术的患者进行沟通。
核心结论
- 所提出的HNSRI在研究人群中对于主要术后不良事件和死亡表现出较高的灵敏度和特异度。
- 该风险指数可用于与等待头颈癌手术的患者进行沟通。
研究设计与样本
- 多医疗中心队列分析,患者来自2006至2016年美国外科医师学会(ACS)国家手术质量改进计划(NSQIP)数据库,接受住院头颈癌切除或重建手术。
- 共纳入31399例手术,患者平均(SD)年龄56.9(15.4)岁,其中女性16994例(54.1%)。
主要发现
- 4556例(14.5%)患者发生主要术后不良事件,209例(0.7%)死亡。
- 多因素回归分析显示,高龄、男性、吸烟、抗凝、近期体重减轻、功能依赖、游离组织移植、气管切开、手术时长、伤口分类、贫血、白细胞增多和低白蛋白血症与主要不良事件或死亡独立相关(C统计量0.83)。
- 验证队列(n=15699)中HNSRI预测主要不良事件(含死亡)的AUC为0.84(95%CI 0.83-0.85),灵敏度80.1%(95%CI 79.4%-80.8%),特异度72.3%(95%CI 70.3%-74.2%)。
- HNSRI预测不良事件优于现有风险模型:相较于改良衰弱指数11的delta C指数为0.23(95%CI 0.22-0.25),相较于美国麻醉医师学会分级为0.14(95%CI 0.13-0.16),相较于ACS风险计算器为0.02(95%CI 0.01-0.03)。
关键数值与推荐
- 主要术后不良事件为复合变量,包括术后30天内死亡。
- HNSRI预测主要不良事件(含死亡)的AUC为0.84(95%CI 0.83-0.85),灵敏度80.1%(95%CI 79.4%-80.8%),特异度72.3%(95%CI 70.3%-74.2%)。
- HNSRI相较于改良衰弱指数11的delta C指数为0.23(95%CI 0.22-0.25),相较于美国麻醉医师学会分级为0.14(95%CI 0.13-0.16),相较于ACS风险计算器为0.02(95%CI 0.01-0.03)。
临床怎么用
- 该风险指数可用于与等待头颈癌手术的患者进行沟通。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients 65 years or older are the most frequent users of operative resources and are also the most vulnerable to postoperative adverse events (AEs). Frailty indices are increasingly being used for preoperative risk stratification within head and neck cancer surgery, but most models lack a multifactorial basis and cannot be directly applied to clinical practice. A practical risk index is needed for clinicians to gauge risk factors preoperatively. OBJECTIVE: To develop a preoperative risk index of short-term major postoperative AEs for patients undergoing head and neck cancer surgery. DESIGN: Cohort analysis of patients from multiple medical centers undergoing inpatient ablative or reconstructive head and neck cancer surgery and registered in the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) from 2006 to 2016. EXPOSURES: Inpatient ablative or reconstructive head and neck cancer surgery. MAIN OUTCOMES AND MEASURES: Sociodemographic, frailty-related, and surgical factors in the derivation cohort were evaluated using simple and multiple logistic regression. Risk factors were subsequently integrated into a preoperative head and neck surgery risk index (HNSRI) and compared with existing models using the validation cohort. A composite variable of major postoperative AEs was used, including death within 30 days of surgery. RESULTS: A total of 43 968 operations were found using the ACS NSQIP database. Of these, 12 569 cases were excluded as non-head and neck cancer or emergency surgery. Of the included 31 399 operations reviewed, the mean (SD) patient age was 56.9 (15.4) years, and 16 994 of the patients were women (54.1%). A total of 4556 (14.5%) patients had a major postoperative AE, and 209 (0.7%) died. Older age, male sex, smoking, anticoagulation, recent weight loss, functional dependence, free-tissue transfer, tracheotomy, duration of surgery, wound classification, anemia, leukocytosis, and hypoalbuminemia were independently associated with major AEs or death on multiple regression analysis (C statistic, 0.83). The area under the curve of the HNSRI to predict major AEs including death using the validation cohort (n = 15 699) was 0.84 (95% CI, 0.83-0.85) with a sensitivity of 80.1% (95% CI, 79.4%-80.8%) and specificity, 72.3% (95% CI, 70.3%-74.2%). The HNSRI outperformed existing risk models for prediction of AEs: delta C index of the HNSRI to the modified frailty index 11, 0.23 (95% CI, 0.22-0.25); the American Society of Anesthesiologists classification, 0.14 (95% CI, 0.13-0.16); and the ACS risk calculator, 0.02 (95% CI, 0.01-0.03). CONCLUSIONS AND RELEVANCE: The proposed HNSRI demonstrated a high sensitivity and specificity for major postoperative AEs and death in the studied population. This risk index can be used to counsel patients awaiting head and neck cancer surgery.
引用
- Mascarella MA, Richardson K, Mlynarek A, et al. Evaluation of a Preoperative Adverse Event Risk Index for Patients Undergoing Head and Neck Cancer Surgery. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 30789650. doi:10.1001/jamaoto.2018.4513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。